Brought to you jointly by

Dr. Jon Bloom is a board-certified physician and entrepreneur with over 15 years of experience in technology development, patient monitoring, biomedical research, and health care delivery.  He is the chief executive officer of Podimetrics, a care management company with the leading solution to help prevent diabetic foot ulcers, one of the most debilitating and costly complications of diabetes. Dr. Bloom co-founded Podimetrics in 2011 while a student at the MIT Sloan School of Management. Podimetrics combines an FDA-cleared SmartMat™ with wraparound care management to spot signs of ulcers, on average, five weeks before they usually would present clinically. By combining cutting-edge technology with best-in-class care management, Podimetrics earns high engagement rates from patients and achieves unparalleled outcomes saving limbs, lives, and money. Dr. Bloom served as a Clinical Assistant Professor and staff anesthesiologist at the University of Pittsburgh Medical Center. He also served as the Director of Global Medical Affairs for Covidien’s Respiratory and Monitoring Solutions division in Boulder, Colorado. Dr. Bloom is a diplomate of the American Board of Anesthesiology, completing residency at the Massachusetts General Hospital. He has co-authored more than 20 peer-reviewed publications with a primary focus on health care economics and perioperative complications.

Arpa Garay is the current President of Global Pharma at Merck.  Prior to this role, Arpa was Senior Vice President, US Vaccines, leading a team across the US to expand vaccine coverage to improve public health and deliver on business objectives, leading a team across the US to expand vaccine coverage to improve public health and deliver on business objectives. She was also the Managing Director of Norway, where she worked closely with the government on healthcare policy, developed innovative approaches to securing patient access, and led the subsidiary to become the #1 pharmaceutical company in the country. She brings to Merck extensive experience and success in strategic planning, marketing expertise, and collaborative management across a wide range of therapeutic areas and healthcare systems. She also brings with her a deep understanding of the US market and evolving global healthcare landscape. She has been externally recognized for her leadership as Fortune’s Most Powerful Women: Next Gen, Business Insider’s Global Top 30 under 40 in BioPharma, and Philadelphia Business Journal’s Top 40 under 40 business leaders. Arpa holds a Bachelor of Science in Economics from the Massachusetts Institute of Technology, where she focused on medicine, public health and public policy. She currently lives outside of Philadelphia with her husband and three children.

Dr. Thomas Osborne is the Director for the newly established VA National Center for Collaborative Healthcare Innovation (NCCHI) and is also the Chief Medical Informatics Officer (CMIO) at VA Palo Alto Healthcare System. He is currently leading multidisciplinary teams in the co-development of pioneering healthcare solutions with industry, government, and VA. His work has been published in numerous medical journals and textbooks with a focus on related topics such as artificial intelligence, predictive analytics, and the future of health care. Dr. Osborne received his medical degree from Dartmouth Medical School, completed his residency at Mount Auburn Hospital, and fellowship at Massachusetts General Hospital. He is board certified in both Diagnostic Radiology and Neuroradiology. Dr. Osborne is a staff neuroradiologist at VA Palo Alto Healthcare System and Clinical Assistant Professor (affiliated) at Stanford.

Matthew W. State MD, PhD, is a child psychiatrist and human geneticist studying pediatric neuropsychiatric syndromes. His lab focuses on gene discovery as a launching point for efforts to illuminate the biology of these conditions and to develop novel and more effective therapies. Dr. State received his undergraduate and medical degrees at Stanford University, completed his residency in psychiatry and fellowship in child psychiatry at the UCLA Neuropsychiatric Institute, and earned a PhD in genetics from Yale University working in the lab of David C Ward. He is currently the Oberndorf Family Distinguished Professor and Chair of Psychiatry at UCSF and Director of the Langley Porter Psychiatric Institute and Hospital. Dr. State’s lab has played a leading role in demonstrating the contribution of rare and de novo variation to autism spectrum disorders (ASD), Tourette disorder (TD), and brain malformation syndromes. Recent work has contributed to the identification of dozens of ASD risk genes, the identification of the first high confidence TD genes, and has utilized systems biological approaches to characterize the spatial and temporal convergence of autism genes in developing human brain. Dr. State plays a leadership role in a number of national and international collaborative genomics studies of autism and Tourette disorder, including the Simons Simplex Collection Genomics Consortium, the Autism Sequencing Consortium, and the Tourette International Collaboration (TIC) on Genetics.